Amanda McDowell

What clinical trial statistics tell us about the state of research today

Recruiting patients for a clinical trial can be a challenging process. Studies show that many patients report having little or no knowledge of clinical trials, and sponsors and researchers often report having difficulties finding and enrolling patients in studies. However, once patients understand more about the medical research process, many individuals do want to participate in a clinical trial.

Continue reading

9 common misconceptions about clinical trial participation

Connecting patients with clinical research opportunities is our mission here at Antidote, but often, we find that misconceptions can serve as barriers to achieving this goal. It’s important to carefully weigh the pros and cons of participating in a clinical trial but to do this effectively, it’s critical to have accurate information.

Continue reading

Talk of the Towne episode 08: ZERO Prostate Cancer

Antidote’s podcast, Talk of the Towne, hosted by Antidote’s Senior Clinical Informatics Manager, Dr. Richard Towne, is an interview series featuring members of Antidote's partner network. During each episode, Rich and his guests take a closer look at particular therapeutic areas, the latest research developments, and specific pain points that impact the patient population.

Continue reading

Understanding the idiopathic pulmonary fibrosis patient community [whitepaper]

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that results in weakened breathing and reduced lung function. In the U.S., it is estimated that 50,000 individuals are diagnosed with IPF each year, and 140,000 are estimated to live with the disease in America.

Continue reading

Antidote receives second consecutive EcoVadis Silver Award

We are excited to announce that we have received the Silver Award from EcoVadis for the second year in a row. EcoVadis is the world’s largest, most trusted provider of business sustainability ratings, with a global network of more than 90,000 companies. Antidote was evaluated within this network to receive this award, and scored in the top 25% of companies focusing on Corporate and Social ...

Continue reading

What do patients know about clinical trials? [Antidote 2023 survey data]

In the third quarter of 2018, we conducted a survey with SCORR Marketing to learn more about the patient perception of clinical trial participation. This extensive survey involved nearly 4,000 patients from our patient advocacy group partners and provided valuable insights into the demographics of these individuals, their motivations for engaging in research, and what matters most to them ...

Continue reading

A World Alzheimer's Month resource roundup

Alzheimer’s disease, the most prevalent type of dementia, is diagnosed in more than 6 million Americans. Estimates project that by 2050, 13 million individuals will be diagnosed with Alzheimer’s disease. This condition ranks among the top 10 causes of death in the United States, profoundly impacting those diagnosed, their loved ones, and their caregivers. Currently, Alzheimer’s remains a disease ...

Continue reading

5 reasons why it's so hard to find clinical trial volunteers

Globally, there are thousands of research studies and clinical trials conducted each year, all with the shared goal of bringing new treatment options and medical devices to the market. However, approximately 80% of clinical trials are delayed or closed because of problems with recruitment.

Continue reading

Come see us at DPharm 2023

Are you attending the 13th annual DPharm conference in Boston on September 20-23?

Continue reading

Antidote Technologies joins forces with Beyond Type 1 and JDRF to launch the first-ever Spanish-language clinical trial search engine for type 1 diabetes (T1D)

Today, Antidote is excited to announce our collaboration with Beyond Type 1 and JDRF to release the first-ever Spanish-language clinical trial search engine for type 1 diabetes (T1D). This groundbreaking version of Antidote Match™ empowers users to search for type 1 diabetes trials in their preferred language, marking a significant step to improve diversity, equity, and inclusion in diabetes ...

Continue reading

Get our latest posts in your inbox